U.S. market Closed. Opens in 2 days 4 hours 19 minutes

INKT | MiNK Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 9.91 - 10.38
52 Week Range 4.56 - 19.00
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 6,245
Average Volume 33,747
Shares Outstanding 3,954,997
Market Cap 39,945,470
Sector Healthcare
Industry Biotechnology
IPO Date 2021-10-15
Valuation
Profitability
Growth
Health
P/E Ratio -2.73
Forward P/E Ratio N/A
EPS -3.70
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 31
Country USA
Website INKT
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
*Chart delayed
Analyzing fundamentals for INKT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is very poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see INKT Fundamentals page.

Watching at INKT technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on INKT Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙